

Date: 14th February 2022

Direct Healthcare Professional Communication (DHPC)

Mavenclad® (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring

Dear Healthcare Professional,

Merck Serono Limited (“Merck”) in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency, would like to inform you about adverse events of liver injury under the treatment with Mavenclad (cladribine):

Summary

- **Liver injury, including serious cases, has been reported in patients treated with Mavenclad (cladribine).**
- **Before initiating treatment, a detailed patient history of underlying liver disorders or episodes of liver injury with other medicines should be undertaken.**
- **Liver function tests including serum aminotransferase (alanine aminotransferase ALT & aspartate aminotransferase AST), alkaline phosphatase, and total bilirubin levels should be assessed prior to initiation of therapy in year 1 and year 2.**
- **During treatment, liver function tests should be conducted, and repeated as necessary. In case a patient develops liver injury, treatment with Mavenclad (cladribine) should be interrupted or discontinued, as appropriate.**

Background on the safety topic

Mavenclad (cladribine) is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.

Liver injury, including serious cases and cases leading to discontinuation of treatment, has been reported in patients treated with Mavenclad (cladribine). A recent review of available safety data has concluded on an increased risk for liver injury following treatment with Mavenclad (cladribine).

Most cases of liver injury concerned patients with mild clinical symptoms. However, in rare cases, a transient serum transaminase (ALT & AST) elevation exceeding 1000 units per litre and jaundice was described. Time to onset varied, with most cases occurring within 8 weeks after the first treatment course.

The review of liver injury cases did not identify a clear mechanism. Some patients had a history of previous episodes of liver injury with other medicines or had underlying liver disorders. Data from clinical trials did not suggest a dose dependent effect.

Liver injury will be included in the product information of Mavenclad (cladribine) as an adverse drug reaction of uncommon frequency. In addition, the product information will be updated with new warnings and precautions regarding liver injury, including recommendations to obtain patient history for underlying liver disorders or previous liver injury, and to assess liver function tests prior to treatment initiation in year 1 and 2.

The prescribers’ guide and the patient guide for Mavenclad (cladribine) will be updated to include information about liver adverse events. Patients should be advised to report immediately to their healthcare professional any signs or symptoms of liver injury.



Merck Serono Limited

5 New Square, Bedfont Lakes Business Park,
Feltham, Middlesex TW14 8HA
Tel: +44 (0)20 8818 7200
Fax: +44 (0)20 8818 7267
Registered Number 990823
Job no: GB-MAV-00136 Date of Prep: February 2022

www.merckgroup.com

Merck Serono is a division of Merck KGaA

Call for reporting

Reporting suspected adverse reactions after authorisation of the medicinal product is important to ensure patient safety. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the MHRA Yellow Card Scheme.

You can report adverse drug reactions online via:

- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store

You can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Adverse events should also be reported to Merck Serono Limited by calling: +44 (0) 20 8818 7373 or by emailing: medinfo.uk@merckgroup.com

Company contact point

Should you have any questions or require additional information please contact the Merck Medical Information department on 0208 818 7373 or by email via: Medinfo.uk@merckgroup.com.

Yours sincerely



Dr Stuart Hill Ph.D

Medical Director UK & Republic of Ireland
stuart.hill@merckgroup.com

